MedTrace Logo

A Study of IBI302 in Patients With nAMD

NCT04820452 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 231

Last updated 2024-11-18

No results posted yet for this study

Summary

This is a multi-center, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of IBI302 in subjects with neovascular age-related macular degeneration.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

BIOLOGICAL

Low dose IBI302

Low dose IBI302 intravitreal injection given as every other month after three loading monthly injection

BIOLOGICAL

High dose IBI302

High dose IBI302 intravitreal injection given as every other month after three loading monthly injection

DRUG

Aflibercept

Intraocular injection

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-28
Primary Completion
2023-01-13
Completion
2023-01-13

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04820452 on ClinicalTrials.gov